4 drug(s) with this reaction
5,878 total reports
Product Dose Omission Issue has been reported as an adverse reaction across 4 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 5,878 adverse event reports mention product dose omission issue in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with product dose omission issue, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have product dose omission issue listed in their FDA adverse event reports, sorted by report count:
In addition to product dose omission issue, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
4 drug(s) manufactured by Amgen Inc have product dose omission issue listed in their FDA adverse event reports: APREMILAST, DENOSUMAB, ROMOSOZUMAB-AQQG, IVABRADINE.
There are a combined 5,878 reports of product dose omission issue across 4 Amgen Inc drug(s) in the FDA adverse event database.